parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	genetic association 0.17 (overall 0.11)	0.17
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in choroid plexus epithelial cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	5 Parkinson's papers of 13	0.76
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 2459

ARL17B in dopamine neurons, braak+0.30 (p 0.426) → -0.47 (p 0.204)receipt 2467
ARL17B in oligodendrocytes, braak+0.48 (p 0.190) → -0.16 (p 0.672)receipt 2466

receipt 2467: ARL17B in dopamine neurons, braak

power: full sample +0.03 (p 0.894, n 18), 95% CI -0.44 to +0.49. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.06 (p 0.827, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.02 (p 0.928, n 18). could be the mix.
skeptic: leave-one-out range -0.08 to +0.16, sign flips 6; without severely affected donors +0.03 (p 0.894, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ARL17B in dopamine neurons.

case closed: nothing better to follow up.

receipt 2466: ARL17B in oligodendrocytes, braak

power: full sample +0.04 (p 0.861, n 18), 95% CI -0.43 to +0.50. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.06 (p 0.820, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.04 (p 0.867, n 18). could be the mix.
skeptic: leave-one-out range -0.07 to +0.17, sign flips 5; without severely affected donors +0.04 (p 0.861, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ARL17B in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts